Brawn Biotech Limited - pharma in Delhi, India. FY 2026 financials & compliance.
CIN L74899DL1985PLC022468 Incorporated 07 November 1985 ROC Delhi HQ Delhi, India
Active Listed - BSE: 530207 Public Limited Company pharma
Market Cap
₹6.30 Cr
BRAWN · BSE
Share Price
₹20.99
-0.05% today
Revenue
₹16.98 Cr
FY 2025-26 · +26.2% YoY
EBITDA
−₹0.31 Cr
Margin -1.8%
Net Profit
₹0.96 Cr
FY 2025-26 · +155.2% YoY
P/E (TTM)
31.4x
P/B 2.0x
ROE
22.2%
ROCE 0.0%
Authorised capital
₹4.5 Cr
Registered with MCA

About Brawn Biotech Limited

Data last updated:

Brawn Biotech Limited is a public limited company based in Delhi, India. It operates in the pharmaceutical retail and distribution segment of the pharmaceuticals sector. It was incorporated on 07 November 1985 and has been in existence for over 41 years.

The company is registered with the Registrar of Companies (ROC), Delhi, under CIN L74899DL1985PLC022468. Its GSTIN is 07AAACB2655D1Z4 (Delhi). The company holds 2 GST registrations, all of them active. It is a listed company as per MCA records. Its shares are listed on BSE: 530207.

The company has an authorised share capital of ₹4.5 Cr and a paid-up capital of ₹3 Cr. It was formerly known as Brawn Pharmaceuticals Limited and Brawn Pharmaceuticals Private Limited. It is led by directors including Brij Raj Gupta and Mayank Jain.

Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at First Floor C – 64 Lagpat Nagar – 1, Delhi, India – 110024.

As per the latest standalone financials for FY 2025-26, the company reported a revenue of ₹16.98 Cr, a growth of 26.2% compared to the previous year. For the same year it recorded a net profit of ₹96 Lakh (net margin 5.7%) and EBITDA of -₹31 Lakh (EBITDA margin -1.8%). The net worth stands at ₹4.34 Cr (up 29.2% YoY). Total assets are valued at ₹5.69 Cr (down 49% YoY).

The company is associated with 2 brands: Brawnpharma and Brawn Biotech. As per MCA filings, the company has satisfied charges of ₹30.28 Lakh on record. Court records list 30 cases involving the company, including 25 filed by the company and 5 filed against it; 5 cases are pending. The company has 5 deals on record (5 market trades); the latest was in December 2024. Its 4 peer companies in the Pharma industry (Pharma Retail and Distribution), with the same principal business activity (wholesale trading) are compared by revenue, 1 larger and 3 smaller; the largest is Swaradhya Healthcare Private Limited with revenue of ₹13.65 Cr. The company has 10 MSME Form 1 returns on record between 2019 and 2024, listing 31 overdue payments to 9 micro and small suppliers.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website brawnbiotech.com.

Company details

CIN L74899DL1985PLC022468
Registration Number 022468
Incorporation Date 07 November 1985
ROC Delhi
Listing Status Listed - Listed on BSE (530207)
Company Status Active
Compliance Status Active Compliant

Name history

Brawn Biotech has undergone 4 name changes throughout its history. The current legal name is Brawn Biotech Limited.

Company NameStatus
Brawn Biotech LimitedCurrent
Brawn Pharmaceuticals LimitedPrevious
Brawn Pharmaceuticals Private LimitedPrevious
Brawn Pharmaceuticals LtdPrevious
Brawn Pharmaceuticals P LtdPrevious

Contact details

Brawn Biotech Limited's registered office is in Delhi, Delhi. Its website is brawnbiotech.com. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Social Media
  • Registered Address
    First Floor C – 64 Lagpat Nagar – 1, Delhi, India – 110024
  • Industry
    Pharma, Pharmaceutical Retailers & Distributors

To see the full contact details of Brawn Biotech Limited, buy the company report.

Comprehensive company report
Brawn Biotech Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Brands

Brawn Biotech operates two associated brands: Brawnpharma and Brawn Biotech. Each brand links to its own profile.

BrandDescriptionWebsite
Pharmaceutical formulations are distributed across major healthcare segments.brawnbiotech.com
Pharmaceutical products are developed and distributed by Brawnpharma.brawnpharma.com

Business activity

The main business activity of Brawn Biotech is trade. In detail, this covers wholesale trading.

Main activity group codeMain activityBusiness activity codeBusiness activityShare of turnover
GTradeG1Wholesale Trading

To see the full business activity and turnover split of Brawn Biotech Limited, buy the company report.

Financials of Brawn Biotech Limited

FY 2025-26 filings available

Brawn Biotech Limited reported revenue of ₹16.98 Cr (up 26.2% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Standalone
Revenue
₹16.98 Cr
+26.2% YoY
EBITDA
−₹0.31 Cr
+82.6% YoY
Profit After Tax
₹0.96 Cr
+155.2% YoY
Net Worth
₹4.34 Cr
+29.2% YoY
Total Assets
₹5.69 Cr
-49.0% YoY
Total Debt
Nil

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue16.9813.4616.4922.238.6234.9849.62
Revenue growth+26.2%-18.4%-25.8%+157.9%-75.4%-29.5%-
EBITDA(0.31)(1.78)(1.47)(0.29)(2.00)(0.59)0.74
EBITDA margin-1.8%-13.2%-8.9%-1.3%-23.2%-1.7%+1.5%
Profit before tax0.02(1.80)(1.54)(0.40)(2.11)(0.35)0.83
Net profit0.96(1.74)(1.23)(0.85)(1.64)(0.55)0.60
Net profit margin+5.7%-12.9%-7.5%-3.8%-19.0%-1.6%+1.2%
EPS (₹)3.14(5.80)(4.16)(2.89)(5.48)(1.84)1.97
Balance sheet
Total assets5.6911.168.086.487.468.979.37
Net worth4.343.365.066.317.228.799.26
Total debt0.000.000.000.000.000.000.00
Cash & bank0.280.200.400.440.220.400.40
Net working capital1.958.186.635.355.867.838.29
Cash flow
Cash from operations0.770.05(0.03)0.320.190.03(0.08)
Cash from investing(0.03)(0.24)(0.01)(0.10)(0.30)0.00(0.02)
Cash from financing0.000.000.00(0.01)(0.06)(0.04)(0.05)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue5.626.081.984.314.895.802.263.84
Revenue growth (YoY)+14.9%+4.8%-12.4%+12.2%+48.2%+42.9%--
Other income0.140.140.180.090.090.090.090.00
Total expenses5.706.032.484.324.885.622.814.25
EBITDA(0.08)0.05(0.50)(0.01)0.010.18(0.55)(0.41)
EBITDA margin-1.4%+0.8%-25.3%-0.2%+0.2%+3.1%-24.3%-10.7%
Depreciation0.030.030.030.030.030.030.030.03
Interest0.000.000.000.000.000.000.000.00
Profit before tax0.030.16(0.35)0.050.070.24(0.49)(0.44)
Tax0.000.00(0.94)0.000.000.000.000.00

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 19 Nov 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue5.626.081.984.314.895.802.263.84
Revenue growth (YoY)+14.9%+4.8%-12.4%+12.2%+48.2%+42.9%--
Other income0.140.140.180.090.090.090.090.00
Total expenses5.706.032.484.324.885.622.814.25
EBITDA(0.08)0.05(0.50)(0.01)0.010.18(0.55)(0.41)
EBITDA margin-1.4%+0.8%-25.3%-0.2%+0.2%+3.1%-24.3%-10.7%
Depreciation0.030.030.030.030.030.030.030.03
Interest0.000.000.000.000.000.000.000.00
Profit before tax0.030.16(0.35)0.050.070.24(0.49)(0.44)
Tax0.000.00(0.94)0.000.000.000.000.00
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue16.9813.4616.4922.238.6234.9849.62
Revenue growth+26.2%-18.4%-25.8%+157.9%-75.4%-29.5%-
Other income0.450.090.090.010.000.310.17
Total expenses17.2915.2417.9622.5210.6235.5748.88
Employee cost0.681.131.401.401.802.363.08
EBITDA(0.31)(1.78)(1.47)(0.29)(2.00)(0.59)0.74
EBITDA margin-1.8%-13.2%-8.9%-1.3%-23.2%-1.7%+1.5%
Depreciation0.120.110.100.110.050.030.03
Interest0.000.000.060.010.060.040.05
Profit before tax0.02(1.80)(1.54)(0.40)(2.11)(0.35)0.83
Tax(0.94)(0.06)(0.30)0.45(0.47)0.200.23
Net profit0.96(1.74)(1.23)(0.85)(1.64)(0.55)0.60
Net profit margin+5.7%-12.9%-7.5%-3.8%-19.0%-1.6%+1.2%
EPS (₹)3.14(5.80)(4.16)(2.89)(5.48)(1.84)1.97
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital3.003.003.003.003.003.003.00
Reserves & surplus1.340.362.063.314.225.796.26
Shareholders' funds (net worth)4.343.365.066.317.228.799.26
Secured loans0.000.000.000.000.000.000.00
Unsecured loans0.000.000.000.000.000.000.00
Total debt0.000.000.000.000.000.000.00
Total liabilities5.6911.168.086.487.468.979.37
Assets
Gross block1.051.020.780.770.670.380.38
Net block0.360.460.330.370.380.140.18
Capital work in progress0.000.000.000.000.000.000.00
Investments0.000.000.000.000.000.000.00
Inventories10.0610.476.024.794.720.260.39
Sundry debtors3.553.413.885.322.819.2815.00
Cash & bank balances0.280.200.400.440.220.400.40
Loans & advances3.233.432.842.854.432.793.42
Total current assets17.1217.5113.1413.4012.1812.7319.21
Total current liabilities15.179.336.518.056.324.9010.92
Net working capital1.958.186.635.355.867.838.29
Total assets5.6911.168.086.487.468.979.37
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash0.200.000.440.220.400.400.54
Net cash from operating activities0.770.05(0.03)0.320.190.03(0.08)
Net cash from investing activities(0.03)(0.24)(0.01)(0.10)(0.30)0.00(0.02)
Net cash from financing activities0.000.000.00(0.01)(0.06)(0.04)(0.05)
Net change in cash0.74(0.20)(0.04)0.21(0.17)0.00(0.14)
Closing cash0.280.200.400.440.220.400.40
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+26.2%-18.4%-25.8%+157.9%-75.4%-29.5%-
EBITDA growth+82.6%-21.1%-406.9%+85.5%-239.0%-179.7%-
PBT growth+9998.0%-16.9%-285.0%+81.0%-502.9%--54.4%
Net income growth+155.2%-41.5%-44.7%+48.2%-198.2%-191.7%-
Revenue CAGR (3Y)-8.6%+16.0%-22.2%-23.5%-49.1%-14.4%-6.4%
EBITDA CAGR (3Y)+2.3%-3.8%+35.6%----15.6%
Profitability & leverage
Net income margin+5.7%-12.9%-7.5%-3.8%-19.0%-1.6%+1.2%
Return on capital employed0.0%0.0%-20.5%-5.7%-25.0%-3.5%+9.6%
Return on net worth+22.2%0.0%-22.0%-12.9%-20.5%-6.1%+6.6%
Debt / equity0.000.000.000.000.000.000.00
Long-term debt / equity0.000.000.000.000.000.000.00
Interest cover0.000.00-3.82-2.50-2.93-6.457.04
Efficiency & per share
Fixed asset turnover16.4114.9621.2830.8816.4292.05132.32
Inventory turnover1.651.633.054.683.46107.63135.95
Debtors turnover4.883.693.585.471.432.883.15
EPS (₹)3.14(5.80)(4.16)(2.89)(5.48)(1.84)1.97
Dividend per share (₹)0.000.000.000.000.000.000.00
Book value per share (₹)14.4611.2116.8821.0324.0729.3130.87

To see the full year-wise statements and ratios of Brawn Biotech Limited, buy the company report.

Board of directors of Brawn Biotech Limited

Brawn Biotech has 3 current directors and 19 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Brij Raj GuptaDirector07 Nov 198541 Years 0 MonthsCurrent
Mayank JainDirector27 Aug 20242 Years 2 MonthsCurrent
Pooja JhaDirector27 Aug 20242 Years 2 MonthsCurrent

Peer comparison

Brawn Biotech Limited is compared with the 4 companies closest to it by revenue in the Pharma industry (Pharma Retail and Distribution), with the same principal business activity (wholesale trading), from the latest filed financials of each company.

CompanyRevenueNet profitMarginGrowth (1 yr)EmployeesLocation
Brawn Biotech Limitedthis company₹16.98 Cr (FY 2026)₹96 Lakh5.7%26.2%Delhi, India
Swaradhya Healthcare Private Limited₹13.65 Cr (FY 2025)-8.0%Lajpat Nagar, Uttar Pradesh, India
Sri Devi Distributors Private Limited₹13.52 Cr (FY 2024)30.0%Chennai, Tamil Nadu, India
Ryvis Pharma Private Limited₹13.51 Cr (FY 2024)44.0%New Delhi, Delhi, India
Vivan Acidchem Private Limited₹13.5 Cr (FY 2022)6.0%Indore, Madhya Pradesh, India

To see the full peer comparison of Brawn Biotech Limited, buy the company report.

Auditor

Brawn Biotech Limited is audited by RAJIV UDAI AND ASSOCIATES for the financial year 2022.

Auditor firmFinancial yearFirm registration number
RAJIV UDAI AND ASSOCIATESFY 2022018764N

Shareholding

Shareholding for the quarter ended Mar 2026: promoters hold 52.90%, foreign institutional investors hold 0.00%, domestic institutional investors hold 0.40% and retail and other public shareholders hold 46.70%.

Promoters: 52.90%DII (Domestic Institutional): 0.40%Retail & Others: 46.70%
Mar 2026
QUARTER
52.90% Promoters
0.40% DII (Domestic Institutional)
46.70% Retail & Others
Promoter holding - history
Now 52.90% · Mar 2026High 53.70% · Jun 2025Low 52.90% · Mar 2026
51%52%53%54%55%Jun 2025Sep 2025Dec 2025Mar 2026Jun 2025: 53.70%Sep 2025: 53.70%Dec 2025: 53.40%Mar 2026: 52.90%53.70%52.90%
Shareholding trend - last 6 quarters
Mar 2026Dec 2025Sep 2025Jun 2025
Promoters52.90%53.40%53.70%53.70%
Public47.10%46.60%46.30%46.30%

Charges & borrowings

Open charges
None
Satisfied charges
₹30.28 Lakh
Breakdown by lending institutions
Punjab National Bank₹0.30 Cr
Latest charge details
DateCharge IDLenderAmountStatusModified or satisfied on
21 Apr 201510568782Punjab National Bank₹6.74 LakhSatisfied
21 Apr 201510569321Punjab National Bank₹6.74 LakhSatisfied
09 Apr 201410501704Punjab National Bank₹14.6 LakhSatisfied
01 Sep 201110313800Punjab National Bank₹2.2 LakhSatisfied

To see the full charge records of Brawn Biotech Limited, buy the company report.

Total charge records: 4 View all charges

Deals & funding

Brawn Biotech Limited has 5 deals on record (5 market trades); the latest was in December 2024.

Total deals
5
Market trades
5

Deals on record (5 of 5)

WhenDealAmountParties
Dec 2024Market trade₹4 LakhBuyer: an individual
Seller: an individual
Jan 2016Market trade₹10.7 LakhSeller: an individual
Jun 2009Market trade₹4.3 LakhSeller: an individual
May 2009Market trade₹5.3 LakhSeller: an individual
Sep 2005Market trade₹10.9 LakhBuyer: an individual

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

MSME payment delays

Brawn Biotech Limited has 10 MSME Form 1 returns on record between 2019 and 2024, listing 31 overdue payments to 9 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.

Suppliers with reported dues (5 of 9)

SupplierAmount dueDue sinceReported on
Stalwart Facilities
an individual supplier
an individual supplier
an individual supplier
Triage Meditech Private Limited

To see the full MSME payment records of Brawn Biotech Limited, buy the company report.

Individuals and sole proprietors among the suppliers are not named.

GST

Brawn Biotech has 2 GST registrations: 2 active.

Total GSTINs
2
Active
2
GSTINStateStatusRegistered on
07AAACB2655D1Z4DelhiActive25 Sep 2017
06AAACB2655D1Z6HaryanaActive01 Jul 2017

To see the full GST registrations and return filing status of Brawn Biotech Limited, buy the company report.

Recent activity

Brawn Biotech Limited has 31 board changes on record since 1985: 17 appointments and 14 cessations. The latest: Brij Bala Gupta ceased to be Director on 25 Nov 2025.

Filing
Brawn Biotech Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Delhi I.
Ceased
Brij Bala Gupta ceased to be Director.
AGM
Brawn Biotech Limited last Annual general meeting of members was held on 30 Sep 2025 as per latest MCA records.
Ceased
Kanta Takkar ceased to be Director.
Appointed
Mayank Jain was appointed as Director.
Appointed
Pooja Jha was appointed as Director.
Ceased
Subhash Chander ceased to be Director.
Ceased
Arun Mudgal ceased to be Director.
Charges
A charge registered on 21 Apr 2015 via Charge ID 10568782 with Punjab National Bank was fully satisfied on 20 Feb 2019.
Charges
A charge registered on 21 Apr 2015 via Charge ID 10569321 with Punjab National Bank was fully satisfied on 20 Feb 2019.
Charges
A charge registered on 01 Sep 2011 via Charge ID 10313800 with Punjab National Bank was fully satisfied on 20 Feb 2019.
Charges
A charge registered on 09 Apr 2014 via Charge ID 10501704 with Punjab National Bank was fully satisfied on 15 Feb 2019.

30 earlier events are in the company report.

Frequently asked questions

Brawn Biotech is an active public limited company based in Delhi, India. The company works in pharmaceutical retailers and distributors, within the pharma industry. It was incorporated on 07 November 1985 (41+ years old) and is registered under CIN L74899DL1985PLC022468. Listed on BSE: 530207.

Brawn Biotech reported revenue of ₹16.98 Cr for FY 2025-26 (up 26.2% YoY) based on standalone financials.

Brawn Biotech has 3 current directors:

The latest financial statements of Brawn Biotech on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 30 September 2025. Year-wise statements from 2015 are in the company report.

The GSTIN of Brawn Biotech is 07AAACB2655D1Z4, registered in Delhi. The company has 2 GST registrations in all, of which 2 are active. Other active GSTINs include 06AAACB2655D1Z6 (Haryana).

The CIN (Corporate Identification Number) of Brawn Biotech is L74899DL1985PLC022468. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Yes. Brawn Biotech is a listed company as per MCA records. Its shares are listed on BSE (code: 530207).

Brawn Biotech has 30 court cases on record: 25 filed by the company and 5 filed against it. 5 are pending. Most are in the district courts.

Brawn Biotech was incorporated on 07 November 1985, making it 41+ years old. It is registered with the Registrar of Companies, Delhi.

Brawn Biotech has 5 deals on record (5 market trades); the latest was in December 2024.

The peers of Brawn Biotech by revenue are Swaradhya Healthcare Private Limited, Sri Devi Distributors Private Limited, Ryvis Pharma Private Limited, Vivan Acidchem Private Limited, all in the Pharma industry (Pharma Retail and Distribution), with the same principal business activity (wholesale trading).

Brij Bala Gupta ceased to be Director on 25 Nov 2025. Kanta Takkar ceased to be Director on 27 Aug 2024. Mayank Jain was appointed as Director on 27 Aug 2024. Brawn Biotech has 31 board changes on record in total.